Clinical trial
The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome in Breast Cancer Patients: A Multicenter, Phase III, Randomized, Double-blind, Controlled Trial
NCT05165069 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome in Breast Cancer Patients: A Multicenter, Phase III, Randomized, Double-blind, Controlled Trial
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- January 1, 2022
- Completion date
- December 31, 2030
- Enrollment
- 234 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.